Eleanor McFadden

21.0k total citations · 2 hit papers
13 papers, 10.1k citations indexed

About

Eleanor McFadden is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Eleanor McFadden has authored 13 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Economics and Econometrics. Recurrent topics in Eleanor McFadden's work include Economic and Financial Impacts of Cancer (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Breast Cancer Treatment Studies (2 papers). Eleanor McFadden is often cited by papers focused on Economic and Financial Impacts of Cancer (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Breast Cancer Treatment Studies (2 papers). Eleanor McFadden collaborates with scholars based in United States, United Kingdom and Italy. Eleanor McFadden's co-authors include Douglass C. Tormey, Paul P. Carbone, Martin M. Oken, John Horton, Thomas E. Davis, Richard H. Creech, Luca Gianni, David Cameron, Evandro de Azambuja and N. Al-Sakaff and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Cancer.

In The Last Decade

Eleanor McFadden

13 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 8.9k citations Martin M. Oken, Richard H. Creech et al. American Journal of Clinical Oncology profile →
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →

Peers

Eleanor McFadden

ONCOL

PRM

SURGE

PHEOH

PFM

Lodovico Balducci United States

Richard H. Creech United States

B. Miller United States

Otto Visser Netherlands

Mark F. Munsell United States

Lisa Rybicki United States

Linda C. Harlan United States

Martin Krapcho United States

Elena B. Elkin United States

Douglass C. Tormey United States

Lodovico Balducci United States

Eleanor McFadden

5.8k ×1.2

ONCOL

2.9k ×0.9

PRM

1.3k ×0.6

SURGE

1.5k ×1.3

PHEOH

944 ×0.9

PFM

Citations per year, relative to Eleanor McFadden Eleanor McFadden (= 1×) peers Lodovico Balducci

Countries citing papers authored by Eleanor McFadden

Since Specialization

Citations

This map shows the geographic impact of Eleanor McFadden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleanor McFadden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleanor McFadden more than expected).

Fields of papers citing papers by Eleanor McFadden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleanor McFadden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleanor McFadden. The network helps show where Eleanor McFadden may publish in the future.

Co-authorship network of co-authors of Eleanor McFadden

This figure shows the co-authorship network connecting the top 25 collaborators of Eleanor McFadden. A scholar is included among the top collaborators of Eleanor McFadden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleanor McFadden. Eleanor McFadden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →

2.

Tutt, Andrew, Bella Kaufman, Judy E. Garber, et al.. (2017). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Annals of Oncology. 28. v67–v67. 16 indexed citations

3.

Jackisch, C, M. Piccart, RD Gelber, et al.. (2016). Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. Cancer Research. 76(4_Supplement). PD5–1. 8 indexed citations

4.

Bretthauer, Michael, Michał F. Kamiński, Magnus Løberg, et al.. (2016). Population-Based Colonoscopy Screening for Colorectal Cancer. JAMA Internal Medicine. 176(7). 894–894. 214 indexed citations

5.

McFadden, Eleanor, Steve Canham, Janet Darbyshire, et al.. (2014). The impact of registration of clinical trials units: The UK experience. Clinical Trials. 12(2). 166–173. 22 indexed citations

6.

McFadden, Eleanor. (2007). Management of Data in Clinical Trials. Wiley series in probability and statistics. 16 indexed citations

7.

McFadden, Eleanor, et al.. (1995). Approaches to data management. Controlled Clinical Trials. 16(2). 30–65. 26 indexed citations

8.

McFadden, Eleanor. (1991). Intergroup participation—The challenge of multigroup trials. Controlled Clinical Trials. 12(5). 674–675. 1 indexed citations

9.

Pandya, Kishan J., Eleanor McFadden, Leslie A. Kalish, et al.. (1985). A retrospective study of earliest indicators of recurrence in patients on eastern cooperative oncology group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer. 55(1). 202–205. 49 indexed citations

10.

Begg, Colin B., Marvin Zelen, Paul P. Carbone, et al.. (1983). Cooperative groups and community hospitals. Measurement of impact in the community hospitals. Cancer. 52(9). 1760–1767. 37 indexed citations

11.

Boice, John D., Mark H. Greene, Susan S. Ellenberg, et al.. (1983). Leukemia and Preleukemia after Adjuvant Treatment of Gastrointestinal Cancer with Semustine (Methyl-CCNU). New England Journal of Medicine. 309(18). 1079–1084. 155 indexed citations

12.

Oken, Martin M., Richard H. Creech, Douglass C. Tormey, et al.. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 5(6). 649–656. 8854 indexed citations breakdown →

13.

Glick, John H., et al.. (1982). Nodular histiocytic lymphoma:Factors influencing prognosis and implications for aggressive chemotherapy. Cancer. 49(5). 840–845. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact